ArticleClinical rheumatology2023
Estimation of the global prevalence, incidence, years lived with disability of rheumatoid arthritis in 2019 and forecasted incidence in 2040: results from the Global Burden of Disease Study 2019.
Article in Clinical rheumatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Evaluation of the risk of heart failure with tumour necrosis factor inhibitors: A large-scale meta-analysis in immune-mediated inflammatory diseases.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Pooled it
- Vaccination and rheumatoid arthritis: an updated systematic review and meta-analysis of data from 25,949,597 participants.BMC public health · 2025Pooled it
- Population PK/PD Modeling and Simulation to Predict the Comparative Long-Term Efficacy of Olokizumab in Rheumatoid Arthritis Patients.Journal of clinical medicine · 2026Article
- Assessing rheumatoid arthritis prevalence from 1990 to 2040: viewing global inequities through the lens of sociodemographic development.Clinical rheumatology · 2026Article
- Review
- Article
- Sex matters: mechanistic insights into sex-driven patterns of autoimmunity and implications for pharmacotherapy.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- The Impact of Comorbidities on Health-Related Quality of Life Among Patients with Rheumatoid Arthritis.Healthcare (Basel, Switzerland) · 2026Article
- Development and validation of a clinical risk prediction rule to identify inflammatory arthritis at the point of rheumatology triage.Rheumatology advances in practice · 2026Article
- Nrf2 as a redox checkpoint in autoimmune joint inflammation: microenvironmental redox control across the arthritis spectrum.Frontiers in immunology · 2026Review
- Type 1 Diabetes and Other Autoimmune Diseases-Epidemiology, Pathophysiology and Screening.Endocrinology, diabetes & metabolism · 2026Review
- Exploring participant experiences with the autoimmune protocol (AIP) diet in rheumatoid arthritis: a longitudinal qualitative study.Journal of nutritional science · 2026Article
- Longitudinal Dynamics of Pain, Fatigue, Anxiety-Depression, Sleep, and Functional Limitation in Older Adults with Rheumatoid Arthritis: A Cross-Lagged Panel Network Analysis.Clinical interventions in aging · 2026Article
- Fibroblast-Neuron interactions Driving persistent Pain in Rheumatoid Arthritis (FiND-Pain RA) - an observational study protocol.BMJ open · 2025Article
- Epigenetic modifications of immune cells in rheumatoid arthritis.Annals of medicine · 2025Review
- Observational
- The Association of Human Parvovirus B19 Infection on the Course of Vietnamese Patients with Rheumatoid Arthritis.Medicina (Kaunas, Lithuania) · 2025Observational
- Epidemiological Study of Childhood Idiopathic Epilepsy from 1990 to 2021 at Global, Regional, and National Scales.Mayo Clinic proceedings. Innovations, quality & outcomes · 2025Article
- Incidence and prevalence of rheumatoid arthritis in Thailand based on National administrative health data and a comprehensive literature review.Scientific reports · 2025Review
- Late-onset rheumatoid arthritis: clinical features, diagnostic challenges, and treatment approaches.Rheumatology international · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveWe aimed to provide a better understanding of the secular trends in rheumatoid arthritis (RA) burden at the regional and national levels, contributing to identifying the areas with high burden needs and finding the potential areas requiring additional attention, which will facilitate the development of strategies tailored to RA burden.
methodData were obtained from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 study. We presented the secular trends in the prevalence, incidence, and years lived with disability (YLDs) of RA needs by sex, age, sociodemographic index (SDI), region, country, and category between 1990 and 2019 using data from the GBD 2019 study. The age-standardized rates (ASR) and its estimated annual percentage changes (EAPCs) are employed to describe the secular trends in RA.
resultsGlobally, there were an estimated 18.5 million [95% confidence interval (CI) 31.53 to 41.74)] prevalent cases of RA, with 1.07 million (95% CI 0.95 to 1.18) incident cases per year and almost 2.43 million YLDs (95% CI 1.68 to 3.28) in 2019. The age-standardized prevalence and incidence rates estimated for RA were 224.25 per 100,000 and 12.21 per 100,000 in 2019, with EAPCs of 0.37 (95% CI - 0.32, 0.42) and 0.30 (95% CI 0.25 to 0.34), respectively. The corresponding age-standardized YLDs estimated was 29.35 per 100,000 in 2019, with an EAPC of 0.38 (95% CI: 0.33, 0.43). During the study period, the ASR of RA was consistently higher in females than in males. Moreover, the age-standardized YLD rate of RA was associated with the sociodemographic index (SDI) in 2019 across all 204 countries and territories (R = 0.28). The projections indicate that the age-standardized incidence rates (ASIR) trend will continue to increase from 2019 to 2040, with a projected ASIR of 10.48 and 4.63/100,000 for females and males, respectively.
conclusionsRA is prevalent and remains a significant global public health challenge. Globally, the burden of RA has increased over the past 30 years and will continue to increase. Prevention and early treatment of RA are pivotal to avoiding disease onset and alleviating the enormous burden. Key Points • The burden of rheumatoid arthritis is increasing globally. • Global estimates indicate that the number of RA incident cases will increase 1.4-fold globally, from approximately 1.07 million at the end of 2019 to approximately 1.5 million by 2040.
Indexed as
Identifiers
37294370What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.